These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 30108799)

  • 1. The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.
    Butterworth S; Cross DAE; Finlay MRV; Ward RA; Waring MJ
    Medchemcomm; 2017 May; 8(5):820-822. PubMed ID: 30108799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.
    Kim DH; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Kim WS; Kim SE; Ryu HC; Kim JS; Guangying L; Choi CM; Rho JK; Lee JC
    Target Oncol; 2018 Jun; 13(3):389-398. PubMed ID: 29754184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.
    Santos ES; Kaplan B; Kirshner E; Croft EF; Sequist LV; Chau M; Munley J; Oxnard GR
    Oncol Ther; 2018 Jun; 6(1):45-58. PubMed ID: 32700141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
    Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
    Li JY; Ho JC; Wong KH
    Oncotarget; 2018 Jun; 9(46):27929-27939. PubMed ID: 29963252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to osimertinib.
    Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
    J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.
    Zhao Z; Li L; Wang Z; Duan J; Bai H; Wang J
    J Cancer; 2020; 11(11):3106-3113. PubMed ID: 32231715
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
    Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
    Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.
    Masuzawa K; Yasuda H; Hamamoto J; Nukaga S; Hirano T; Kawada I; Naoki K; Soejima K; Betsuyaku T
    Oncotarget; 2017 Dec; 8(62):105479-105491. PubMed ID: 29285266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
    Uemura T; Oguri T; Okayama M; Furuta H; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Mol Clin Oncol; 2017 Apr; 6(4):525-528. PubMed ID: 28413660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent dual ALK and EGFR T790M inhibitor.
    Jang J; Son JB; To C; Bahcall M; Kim SY; Kang SY; Mushajiang M; Lee Y; Jänne PA; Choi HG; Gray NS
    Eur J Med Chem; 2017 Aug; 136():497-510. PubMed ID: 28528303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
    Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
    J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients.
    Zheng Q; Hong S; Huang Y; Zhao H; Yang Y; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Clin Transl Med; 2020 Feb; 9(1):17. PubMed ID: 32067121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malcolm Morris Memorial Lecture on THE OUTLOOK ON TUBERCULOSIS: CHANGING ORIENTATION.
    Philip R
    Br Med J; 1931 Jan; 1(3653):43-9. PubMed ID: 20775943
    [No Abstract]   [Full Text] [Related]  

  • 17. The Campbell Memorial Oration.
    Ulster Med J; 1933 Apr; 2(2):139-40. PubMed ID: 20475955
    [No Abstract]   [Full Text] [Related]  

  • 18. "The R. P. Campbell Memorial Fund".
    Can Med Assoc J; 1917 Mar; 7(3):254-5. PubMed ID: 20310927
    [No Abstract]   [Full Text] [Related]  

  • 19. The Meyers Memorial Prize.
    A G N
    Can Med Assoc J; 1939 Aug; 41(2):190-1. PubMed ID: 20321446
    [No Abstract]   [Full Text] [Related]  

  • 20. The Meyers Memorial Prize.
    A G N
    Can Med Assoc J; 1938 May; 38(5):486-7. PubMed ID: 20320971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.